Identiv price target lowered to $6 from $8 at Craig-Hallum

Craig-Hallum lowered the firm’s price target on Identiv to $6 from $8 and keeps a Buy rating on the shares. Identiv is lacking a catalyst this year and the firm hopes the new CEO can find value through strategic partnerships with healthcare companies, the analyst tells investors in a research note. The firm thinks patient investors will ultimately be rewarded as new management takes over post transaction with a focus on stickier healthcare business and expects to nearly double gross margins after shifting production fully to their Thailand facility.